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The First Forty Years
of the Alternatives
Approach:
Refining, Reducing,
and Replacing the Use
of Laboratory Animals

8
CHAPTER

An updated version of “Looking Back Thirty-three Years to Russell and Burch:
The Development of the Concept of the Three Rs (Alternatives)” (Rowan 1994)
Martin L. Stephens, Alan M. Goldberg, and Andrew N. Rowan

Introduction
he concept of the Three Rs—
reduction, refinement, and
replacement of animal use in
biomedical experimentation—stems
from a project launched in 1954 by
a British organization, the Universities Federation for Animal Welfare
(UFAW). UFAW commissioned William
Russell and Rex Burch to analyze the
status of humane experimental techniques involving animals. In 1959
these scientists published a book that
set out the principles of the Three Rs,
which came to be known as alternative methods. Initially, Russell and
Burch’s book was largely ignored, but
their ideas were gradually picked up
by the animal protection community
in the 1960s and early ’70s. In the
’80s, spurred by public pressure, the
alternatives approach was incorporated into national legislation throughout the developed countries and
embraced by industry in Europe and
America. Government centers devoted to the validation and regulatory
acceptance of alternative methods

T

were established during the ’90s. By
2000 the use of animals in research
had fallen by up to fifty percent from
its high in the 1970s.

The Alternatives
Approach in
the Context
of the Animal
Research Issue
Animals have been used as experimental subjects in biomedical research, testing, and education during
the last 150 to 200 years, but the
practice began to burgeon in nineteenth century Europe. Alarmed by
this increase, early critics of animal
research challenged it from several
perspectives. They argued variously
that animal research was cruel and
inhumane; unethical; and medically
unproductive, unnecessary, or even
misleading. Their criticism largely

proved unpersuasive (French 1975;
Turner 1980). Activism in the United
States over animal research waned
after World War I and remained at a
low level until after World War II,
when a new dimension in the animal
research controversy emerged.
Spurred in part by advances in
technological methods, animal protectionists began advocating for
alternatives to laboratory animal use,
not simply advocating against animal
use or otherwise criticizing the status quo. These alternatives make up
the Three Rs: methods that could
replace or reduce laboratory animal
use in specific procedures or refine
such use so that animals experience
less suffering. Sympathetic scientists
joined in this more constructive
approach; indeed, scientists themselves were the ones who first formulated the Three Rs concept. At the
dawn of the twenty-first century, this
approach is proving to be a powerful
force in decreasing the use and distress of animals in experimental biology and medicine.
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Table 1
Alternatives Chronology: 1876–1959
1876

Cruelty to Animals Act—the first law to specifically
regulate animal experimentation—is enacted in
Great Britain.

1954

Universities Federation for Animal Welfare (UFAW)
establishes a committee to study humane techniques
used in laboratory animal experiments.

1927

The LD50 Test is introduced to standardize the
potency of digitalis extract.

1957

1938

The Federal Food, Drug, and Cosmetic Act is enacted,
marking the first time a U.S. government agency
is given the power to regulate consumer products.

UFAW holds a symposium, “Humane Techniques in
the Laboratory,” at which William Russell presents
a paper, marking the first time the Three Rs of
replacement, reduction, and refinement are discussed
in public.

1959
1944

Eye irritancy testing is standardized as the
Draize Test.

Russell and Burch’s study is published as The Principles
of Humane Experimental Technique, which develops
the Three Rs approach at length.

Estimates of the numbers of research animals used annually in the
United States and worldwide are highly speculative. The last official estimate for the United States was 17 to
22 million animals (U.S. Office of
Technology Assessment 1986), but
that study was conducted more than
fifteen years ago. There is some evidence that this estimate was made
during a period of declining animal
use that began in the 1960s and
continued into the ’90s (Rowan et
al. 1995). Consequently, the current
figure could be lower. Worldwide
animal use was estimated to be
between 60 and 85 million animals
in the early 1990s (Rowan 1995),
but more conservative estimates of
rodent use suggest a total of 40 million animals worldwide (D. Kawahara,
personal communication with A.
Goldberg 1998).

The 1950s:
The Three
Rs Approach
Launched
The British scientists William Russell
and Rex Burch formally launched the
Three Rs with their book The Principles of Humane Experimental Technique (Russell and Burch 1959). However, hints of Russell and Burch’s
ideas had appeared in earlier discussions about the appropriate use of
animals in research. Marshall Hall, a
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British experimental physiologist during the first half of the nineteenth
century, proposed five principles for
animal experimentation that would
eliminate unnecessary and repetitive
procedures and minimize suffering
(Manuel 1987). Hall also recommended the use of phylogenetically “lower,”
less sentient, animals and praised the
findings of a colleague who demonstrated that an animal that had just
been killed could be substituted for a
living one, thereby eliminating pain.
Fifty years after Hall set out his
five principles, a short-lived research
foundation—the Leigh Brown Trust—
was established to promote and
encourage scientific research without
inflicting pain on experimental animals (French 1975). Although the
Trust commissioned several publications in the 1890s, it never succeeded
in developing a research program
that convinced a significant proportion of the research community to
adopt its principles. From 1900 to
1950, those who opposed the use of
animals lost much of their political
influence and were relegated to the
fringes of political activity. As a
result, little attention was paid to the
ethical questions posed by the use of
animals in research.
After World War II, interest in the
animal research issue began to grow
again. In the United States, newly
formed animal protection groups
began to criticize animal research
practices. In England the Three Rs
concept of alternatives began to

emerge from the work of UFAW.
UFAW published a handbook on the
care and management of laboratory
animals (Worden 1947) that was well
received. This gave UFAW the confidence to address the more contentious topic of experimental techniques involving animals (as distinct
from animal care). Accordingly, in
1954 Major Charles Hume (the
founder of UFAW and its director at
the time) established a committee to
initiate a systematic examination of
the progress of humane technique in
the laboratory. Hume served as the
committee’s secretary, but it is noteworthy that the committee was
chaired by Peter Medawar, a wellrespected immunologist, and also
included among its members William
Lane-Petter, secretary of the Research
Defence Society, an organization
established to defend animal research.
The committee employed William
Russell (a zoologist) and Rex Burch (a
microbiologist) to carry out the project (Hume 1962).
The exact origin of the Three Rs
concept is not entirely clear (Russell
1995). In a 1959 talk, Hume indicated that Russell was the originator
of the “Three Rs” concept (Hume
1962), while Russell (1995), in a retrospective paper entitled “The Development of the Three Rs Concept,”
credited Hume as our “inspiration and
guide throughout.” In that paper Russell recalled that the Three Rs concept
evolved sometime between the sumThe State of the Animals: 2001

Table 2
Alternatives Chronology: 1960 –1969
1962

Lawson Tait Trust (UK) is established—the first
research fund to support the scientific development
of alternatives.

1967

United Action for Animals is formed in the
United States and later campaigns specifically
for replacement alternatives.

1963

The first edition of The Guide for the Care and Use of
Laboratory Animals, written by the National Academy
of Sciences, is published by the National Institutes
of Health.

1969

The Fund for the Replacement of Animals in
Medical Experiments (FRAME) is formed in the
United Kingdom to promote to the scientific
community the idea of alternatives.

1965

Littlewood Committee Report (UK) concludes that
little would be gained by paying special attention
to alternatives.

1969

Lord Dowding Fund (UK) is established to support
alternatives research.
Sir Peter Medawar correctly predicts the subsequent
worldwide decline in animal use.

mer of 1955 and May 1957. The first
recorded mention of the Three Rs was
on May 7, 1957, at a meeting,
“Humane Technique in the Laboratory,” organized by UFAW and chaired by
Medawar. Russell (1957) gave a presentation at this meeting in which he
described the Three Rs. A brief proceedings (Anonymous 1957) was published later that year by the Laboratory Animals Bureau of the Medical
Research Council. Many of the arguments and ideas presented by Russell
and the other speakers later appeared
in The Principles of Humane Experimental Technique (Russell and Burch
1959). See Table 1 for a chronology of
these and other early developments.
It is noteworthy from an American
perspective that the U.S.-based Animal Welfare Institute (AWI) provided
financial support to Russell and
Burch’s project and that AWI’s Christine Stevens made frequent visits to
England to encourage their work
(Russell 1995).

The 1960s:
Dormancy
Although The Principles of Humane
Experimental Technique has now become the classic text on alternatives, it
received little attention when it was
published in 1959 despite its promotion by UFAW in England and the AWI
in the United States. There are several

examples of the lukewarm reaction to
the book within the scientific community. In Nature, a leading international
science journal based in England,
Weatherall (1959) commented:
[It] is useful to have a résumé
of ways which have already been
adopted to make experimentation
as humane as possible…[but the
book] is not sufficiently informative to be used as guide either to
details of experimental design or
to the husbandry of experimental
animals. Perhaps its chief purpose
is to stimulate thought on both of
these topics, and it is to be hoped
it will succeed in doing so.
The British journal Veterinary
Record (Anonymous 1959) commented that the book contained an important message and hoped that it would
not be relegated “to the shelves merely for reference,” but found the philosophy “somewhat difficult reading.”
The British medical journal The
Lancet (Anonymous 1960) also found
the book difficult going, noting that
“its purpose is admirable, and its matter unexceptionable,” but “it is not
easy reading.” It is not clear whether
the tepid reviews reflected a general
lack of interest in the topic or were a
reaction to the book’s arguments (a
contemporaneous Nature review of a
book that defended the use of animals [LaPage 1960] was, by contrast,
full of praise).
LaPage’s (1960) defense of animal
research described the contributions

of animal research to medical advance and mentioned Russell and
Burch and the concept of the Three
Rs only once, in a final chapter. He
noted that distinguished scientists at
a UFAW meeting
discussed, among other things,
how the numbers of laboratory
animals used, and the numbers of
experiments done on them, could
be reduced, how their welfare
could be improved, how the techniques used could be refined and
how far, as Russell and Burch
(1959) also discuss, animals could
be replaced, for certain kinds of
experiments at any rate.
After the initial book reviews and
aside from the occasional mention of
the idea of alternatives in the technical literature, the scientific community largely ignored Russell and
Burch’s book for nearly two decades.
According to an analysis by Phillips
and Sechzer (1989), the term “alternatives” did not appear in the scientific literature on the animal research
issue in the 1960s, aside from a 1966
paper alluding to the concept.
During the 1960s, the animal protection community occasionally heeded Russell and Burch’s 1959 call for
alternatives (Table 2). In 1962 three
leading antivivisection societies in
the United Kingdom (the British
Union for the Abolition of Vivisection,
the National Antivivisection Society
[NAVS], and the Scottish Society for
the Prevention of Vivisection) estab-
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lished the Lawson Tait Trust to
encourage and support researchers
who were not using any animals in
their research. In 1967 United Action
for Animals was established in the
United States to promote alternatives, focusing on the principle of
replacement. It’s founder, Eleanor
Seiling, spent many hours in the New
York Public Library poring through
scientific journals looking for examples of unnecessary animal research
and of alternatives. However, she
appears to have been a lone voice in
the United States. By and large the
animal protection literature of the
1960s did not pay much attention to
the idea of alternatives.
Aside from these few examples of
individuals taking up Russell and
Burch’s challenge in the years immediately following publication of their
book, their ideas did surface directly
or indirectly from time to time. In the
early 1960s, the British Home Office
set up a Committee of Inquiry into
the workings of the 1876 Cruelty to
Animals Act, chaired by Sir Sidney
Littlewood. The Littlewood Committee report (1965) addressed the
question of alternatives only briefly,
but the mention at least indicated
that the issue was beginning to be
raised in public discourse. The Committee reported that it had
repeatedly questioned scientific
witnesses about the existence of
alternative methods which would
avoid the use of living animals.
The replies have been unanimous
in assuring us that such methods
are actively sought and when
found are readily adopted…Discoveries of adequate substitutes
for animal tests have, however, so
far been uncommon, and we have
not been encouraged to believe
that they are likely to be more frequent in the future” (paragraph
71).
The Committee accepted these
arguments and concluded that the
demand for the use of animals in
biomedical research was likely to
increase in the coming years and that
the discovery of substitutes for animal tests was not likely to affect the
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demand for animal experimentation.
In the United States in the early
1960s, pressure from animal protectionists led to several congressional
hearings on bills to regulate animal
research. The printed record of the
1962 hearings is 375 pages long but
apparently contains only one reference to Russell and Burch and none
at all to alternatives (U.S. Congress
1962). The one reference to Russell
and Burch came in testimony by
Hume, still the director of UFAW, who
had been flown to the United States
to testify that the Cruelty to Animals
Act (1876) was well regarded by
British scientists. Also in 1962, The
Humane Society of the United States
(HSUS) published a booklet, Animals
in Research, that alluded to the concept of reduction. The booklet reported the results of an analysis commissioned by The HSUS and carried out
by Westat Research Analysts of the
statistical approach used in published
research papers (Anonymous 1962).
The analysts concluded that the statistical design of the published studies was usually inadequate and that at
least 25 percent fewer animals could
have been used without altering the
validity of the results.
Arguably the most significant development on the alternatives front during the 1960s was the establishment
in 1969 of the U.K.-based charitable
organization FRAME (Fund for the
Replacement of Animals in Medical
Experiments) to promote the concept
of alternatives among scientists.
Although small in size and influence
in its early years, FRAME has become
a powerful force for advancing alternative methods. Also in 1969 the
U.K.-based NAVS set up the Lord
Dowding Fund to support alternatives
research. Both FRAME and the Dowding Fund were relatively well received
by some popular science magazines
(both the New Scientist and World
Medicine praised the new, more scientific approach represented by the two
organizations). Attitudes in the United States were more negative. A 1971
editorial in the Journal of the American Medical Association (Anonymous
1971) criticized FRAME in scathing

terms, commenting that FRAME
might be better named FRAUDS (Fund
for the Replacement of Animals Used
in the Discovery of Science).
By the close of the 1960s, Peter
Medawar, the British scientist who
had encouraged UFAW to undertake
the Russell and Burch project, had
won a Nobel Prize for his work in
immunology and had been knighted
by the British Crown. In a 1969 essay
published a few years later, Medawar
commented presciently on the
prospects for alternatives and a
decrease in animal use:
The use of animals in laboratories
to enlarge our understanding of
nature is part of a far wider
exploratory process, and one cannot assay its value in isolation—as
if it were an activity which, if prohibited, would deprive us only of
the material benefits that grow
directly out of its own use. Any
such prohibition of learning or
confinement of the understanding would have widespread and
damaging consequences; but this
does not imply that we are forevermore, and in increasing numbers,
to enlist animals in the scientific
service of man. I think that the use
of experimental animals on the
present scale is a temporary
episode in biological and medical
history, and that its peak will be
reached in ten years time, or perhaps even sooner. In the meantime, we must grapple with the
paradox that nothing but research on animals will provide us
with the knowledge that will
make it possible for us, one day,
to dispense with the use of them
altogether” (Medawar 1972,
emphasis added).
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Table 3
Alternatives Chronology: 1970 –1979
1970

1971

FRAME publishes Is the Laboratory Obsolete?,
which outlines replacement methodologies such as
computer modeling, tissue culture studies, and the
use of lower organisms.

1978

David Smyth, president of the United Kingdom
Research Defense Society—established to support
animal research—publishes the first book examining
alternatives since the publication of Russell and
Burch’s 1959 work.

Council of Europe Resolution 621 suggests that
an alternatives database be established, the first
significant government recommendation
on alternatives.
Bruce Ames of the University of California at Berkeley
introduces a nonanimal test for detecting mutationcausing substances, later known as the Ames Test,
using a bacterium.

1972

The Felix Wankel Prize (now 50,000 deutsche marks)
for advancing the field of alternatives is offered for
the first time.

1973

FRAME begins to publish ATLA (Alternatives to
Laboratory Animals).

1975

The U.S. National Academy of Sciences holds the
United States’ first major scientific meeting
on alternatives.

1977

The Netherlands Animal Protection Law includes a
specific section on alternatives that has grown into
a program in which the government provides the
equivalent of hundreds of thousands of dollars to
support alternatives research.

The 1970s:
Animal
Protectionists
Heed the Call
During the 1970s, the alternatives
approach became a key theme for the
animal protection movement, which
was growing in both size and political
clout (Rowan 1989). The HSUS established a committee of experts on
alternatives in the early ’70s and later
in the decade published a twenty-five
page booklet on the subject (Rowan
1979). The political and scientific
establishments also began to be
drawn into the debate, as indicated by
some selected events (Table 3). The
first major political initiative on alternatives came in 1971 when the Council of Europe passed Resolution 621.
This proposed, among other things,
the establishment of a documenta-

FRAME hosts “Alternatives in Drug Development
and Testing” at the Royal Society—Europe’s first
big scientific meeting on alternatives.

1979

At the urging of United Action for Animals, the
Research Modernization Act (H.R. 4805), which
would redirect 30–50 percent of animal research
funding to alternatives, is introduced in Congress.
The Swedish government allocates $90,000 in
funding for alternatives—the first government
funding for alternatives.
The Dutch Minister of Health states that the
government supports the use of alternatives.

tion and information center on alternatives and tissue banks for research.
Deliberations on Resolution 621 did
not begin until the late ’70s, and the
ensuing final Council of Europe Convention dropped some of the specific
recommendations on alternatives.
Instead, the Convention reflected the
broad concern over animal research
and made some rather general recommendations on alternatives.
In Europe a number of countries
(for example, Denmark, the Federal
Republic of Germany, the Netherlands,
Sweden, and Switzerland) enacted animal research legislation that included
specific support for alternatives. In
Sweden the government established
an advisory Central Committee on
Experimental Animals to develop and
promote alternatives and allocated
the equivalent of $90,000 annually
for the support of research on alternatives. This represented the first
government funding for alternatives.

In 1977 the Netherlands Animal Protection Law included a specific section on alternatives that has grown
into a program in which the government provides the equivalent of hundreds of thousands of dollars to support alternatives research.
In the United Kingdom, FRAME
began publishing ATLA Abstracts to
identify articles in the scientific literature that focused on alternatives.
While the journal had little impact
when it was simply publishing
abstracts, it started to include review
articles in 1976 and then, early in the
’80s, dropped the abstracts altogether and adopted its current format,
which is centered on original articles.
ATLA (Alternatives to Laboratory
Animals) is now well enough established to be covered by the Science
Citation Index.
In the United States, interest in
alternatives grew slowly. By the
mid-’70s, the term had entered the
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Table 4
Alternatives Chronology: 1980 –1989
1980

American activist Henry Spira launches the Draize
campaign against the rabbit-based eye irritancy test.

1986

As a result of the Draize campaign, Revlon gives a
$750,000 grant to Rockefeller University to establish
an alternatives research program.

The UK’s Animals (Scientific Procedures) Act
replaces the 1876 act.
The U.S. Congress’s Office of Technology Assessment
issues a landmark report, “Alternatives to Animal Use
in Research, Testing and Education.”

The New England Antivivisection Society gives
$100,000 for alternatives research on tissue culture,
and a second animal-welfare consortium provides
$176,000 for Chorio-Allantoic Membrane (CAM)
test development.
1981

1982

1983

CAAT and Bausch and Lomb sponsor a workshop
on alternatives and acute ocular irritation testing.

The Council of Environmental Ministers of the
European Community enacts EC Directive 86/609,
requiring that member countries develop legislation
promoting the Three Rs.

As a result of the Draize campaign, the cosmetics
industry gives $1 million to Johns Hopkins University
to establish the Center for Alternatives to Animal
Testing (CAAT) (Avon and Bristol-Myers Squibb
were the leading donors).

An FDA survey reports a 96 percent decrease in the
use of the classic LD50 tests in 1985 compared with
the period 1975–1979.

Swiss animal legislation specifically requires
consideration of alternatives.

Two new cell toxicology journals, Toxicology In Vitro
and Molecular Toxicology, are established.

Zbinden and Flury-Roversi publish a critique of
the LD50 Test.

The Organization for Economic Cooperation and
Development (OECD) announces changes in its
guidelines for acute oral and dermal toxicity and
starts to discuss alternatives.

Colgate Palmolive provides $300,000 to investigate
the CAM system.
CAAT holds its first symposium.

British Industrial Biological Research Association
(BIBRA) increases funding of alternatives research
to £700,000 per annum.

Switzerland provides two million Swiss francs over
two years for alternatives research.

The Industrial In Vitro Toxicology Society (IVTS)
is established in the United Kingdom.

The Food and Drug Administration (FDA) formally
announces that it no longer requires data from the
classical LD50 Test.

Federal Republic of Germany enacts new laws
on animal protection requiring consideration
of alternatives in animal research.

Utrecht University in the Netherlands establishes
research and education programs directed towards
further implementation of the Three Rs.
1984

FRAME receives £160,000 from the Home Office—the
first UK government funding for alternatives research.

1985

The Health Research Extension Act is passed,
requiring the NIH to develop a plan for alternatives.
Animal Welfare Act amendments are passed,
requiring greater attention to alternatives to research
techniques that cause pain and distress.
Index Medicus, an index of published biomedical
studies, adds the subject heading “Alternatives
to Animal Testing.”

1987

The HSUS publishes an analysis of the historical
importance of alternative methods in biomedical
research awarded Nobel Prizes.
The Dutch Alternatives to Animal Experiments Platform
is established with participation from government,
industry, and animal welfare organizations.
In Vitro Toxicology: A Journal of Molecular and
Cellular Toxicology is established.
The Swiss Foundation “Finanzpool 3 R” is established
to support alternatives research with one million
Swiss francs.
(continued on next page)

The European Research Group into Alternatives
to Toxicity Testing (ERGATT) is formed.
The Soap and Detergent Association (USA) initiates
the In Vitro Alternatives Program.
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Table 4
Alternatives Chronology: 1980 –1989
1988

A government/industry workshop is held on
alternatives in ocular irritancy testing, to review
the Soap and Detergent Association’s Alternatives
Program.
The Industrial In Vitro Toxicology Group holds
its first meeting.
The U.S. Republican presidential platform encourages
the implementation of alternatives to animal testing.
The J.F. Morgan Foundation for Alternatives Research
is established in Canada.
The Swiss government’s Office for Animal
Experiments and Alternatives is established.

1989

The Center for the Documentation and Evaluation of
Alternative Methods to Animal Experiments, known
by its German acronym ZEBET, is established
in Germany.
Procter and Gamble announces that it is contributing
$450,000 per year for three years to its University
Animal Alternative Research Program.
Avon Products announces that it will no longer use
the Draize Test.
The Scandinavian Society for Cell Biology establishes
the Multicenter Evaluation of In Vitro Cytotoxicity
(MEIC) to assess alternatives to LD50 testing for
acute toxicity.
The Second International Conference on Practical
In Vitro Toxicology is held in the United Kingdom.
The Swedish Fund for Scientific Research without
Animal Experiments invests 700,000 Swedish crowns
in alternatives projects.
The Clonetics Corporation begins to market cells
and cell testing methods.
The American Anti-Vivisection Society establishes
the Demeter Fund (later known as the Alternatives
Research and Development Foundation) in order to
support nonanimal research, funding up to $50,000
annually for one or more projects.

vocabulary of the animal movement
on a large scale and had begun to find
its way into the scientific literature
(Phillips and Sechzer 1989). The
National Academy of Sciences (NAS)
organized a meeting on alternatives in
1975 (NAS 1977), but the broader scientific community was not happy
about the idea of alternatives, and
there was much criticism of the Academy for providing a platform for “antivivisectionists” by organizing the
meeting. In the late ’70s, Seiling of
United Action for Animals managed to
persuade a New York congressman to
introduce the Research Modernization Act, which called on the National
Institutes of Health (NIH) to reallocate 30 to 50 percent of all money
spent on animal research to “alternatives” (in the narrow sense of replacement, not the full Three Rs). The Act
caught the imagination of the animal
protection movement in spite of its
vague language and lack of contact

with political realities. This public
pressure then forced Congress to start
to pay attention to alternatives.

The 1980s:
Government
and Industry
Begin to Heed
the Call
The growing pressure from the animal protection community for alternatives paid dividends in the ’80s,
as industry in Europe and America
began to embrace the alternatives
concept and governments played an
increasingly important role (Table 4).
In 1983 Switzerland enacted a legislative requirement for consideration
of alternatives and the government
earmarked two million Swiss francs
over two years for alternatives

research. Five years later the Swiss
government established an office for
animal experiments and alternatives.
In 1986 the Council of Environmental Ministers of the European Communities passed EEC Directive 86/
609, which required member countries to develop enabling legislation
promoting the Three Rs. The Animals
(Scientific Procedures) Act of 1986,
replacing the 1876 Cruelty to Animals Act, was passed in the United
Kingdom. It required greater attention to the issue of animal suffering
(refinement). Also in 1986 the Federal Republic of Germany enacted new
laws on animal protection requiring
consideration of alternatives in
animal research. Three years later
Germany established the Center for
the Documentation and Evaluation
of Alternative Methods to Animal
Experiments, known by its German acronym ZEBET, which spearheaded several government initiatives
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to validate alternative tests. In the
Netherlands government officials
began collecting data on the extent of
the suffering experienced by laboratory animals, and the Organization for
Economic Cooperation and Development (OECD), driven by representatives from Europe, began to address
the Three Rs in their guidelines for
toxicity testing.
Worldwide, probably the most significant event in the ’80s was the
launching of campaigns in many of
the developed countries against animal testing of cosmetics, toiletries,
and household products. These campaigns built on the efforts and publications during the late ’70s by scientists and organizations such as
FRAME, which laid out the scientific
challenges to the routine use of animals in toxicity testing (Balls et al.
1983; Zbinden and Flury-Roversi
1981). The main actor in the U.S. animal protection campaign was labor
and civil rights activist Henry Spira,
who turned his attention to animals
after reading an article by Australian
philosopher Peter Singer (1973).
Spira contacted with activists in England (such as Jean Pink of Animal
Aid, who had been targeting cosmetics testing since 1977), Europe, and
Australia and helped to focus and
coordinate protests against the eye
irritancy testing (the Draize Test) of
cosmetics worldwide.
In the United States, Spira’s campaign built a coalition of four hundred animal protection organizations
that targeted the use of the Draize
Test by cosmetic companies in general and Revlon in particular. Within
twelve months, the coalition’s activities resulted in more than $1.75
million of funding for alternatives
research. The Rockefeller University
received $750,000 from Revlon to
establish a laboratory for in vitro
toxicological assay development, and
the Johns Hopkins University Center
for Alternatives to Animal Testing
(CAAT) was established with $1 million from the Cosmetic, Toiletry, and
Fragrance Association. Avon Products, Bristol-Myers Squibb, and other
companies provided the bulk of the
128

funds for CAAT and also provided
funds for FRAME programs in the
United Kingdom.
The effectiveness of Spira’s campaign was based on several factors.
First, he engaged in extensive preliminary planning and preparation. For
example, Spira acquired numerous
copies of the government Draize Test
training film and slides (showing
inflamed and damaged rabbit eyes)
before the campaign started. (By late
1980 these materials were no longer
being handed out for free by the government to anyone who asked.) Second, he did not shy away from the
hard-nosed street politics he had
learned in the labor and civil
rights campaigns; he made skillful use of demonstrations and the
media. Third, he was always willing
to negotiate with the opposition and
he avoided ad hominem attacks and
insults. This earned him the respect
of his opponents. Fourth, he
engaged in a constant search for
solutions in which everyone could
feel he or she had won something.
(Importantly, he did not boast to the
media about victories over corporate targets.) When Revlon finally
negotiated a settlement with Spira
that set up the Rockefeller alternatives research program, Spira not
only stopped his campaign, but he
also praised Revlon for its innovative
program and invited other cosmetic
companies to take similarly progressive steps.
The Draize campaign initiated
enormous changes in the field of
alternatives in toxicity testing. From
1981 to 1991, there was a tremendous shift in attitude toward alternatives in toxicity testing within industry. Corporate toxicologists who had
gone along with the initial grants for
alternatives research in 1980 and
1981 because they felt such actions
were necessary for public relations
reasons, became excited by the technical and scientific challenge of alternatives by the end of the decade.
Colgate-Palmolive began to fund
research into the Chorio-Allantoic
Membrane (CAM) test in 1982 (to
the tune of $300,000) and within

three years had set up an alternatives
program in its in-house laboratories.
Procter and Gamble and BristolMyers Squibb made the search for
alternatives part of their corporate
culture; they currently provide millions of dollars annually for intramural and extramural alternatives programs. Industrial in vitro toxicology
associations have been started in
both Europe and the United States,
and several toxicology journals specializing in in vitro approaches were
established in the late 1980s. For-profit companies that develop and market
in vitro tests, such as the Clonetics
Corporation and the National Testing
Corporation, later known as In Vitro
International, were established.
Despite all the interest, however,
scientists were still cautious about
relying too heavily on the new in vitro
techniques. Toxicological risk evaluation is a difficult art, and the transformation of alternative methods
from screening tools for preliminary
decision-making to their use as
replacements for whole animals did
not begin to come to fruition until
the 1990s. However, a widespread
consensus emerged during the ’80s
that toxicology testing needed to
move in a different direction. Thus, at
CAAT’s first symposium (in 1982),
the participants mostly wondered if
an alternative to the Draize Test could
be found (Goldberg 1983), but within
five years, participants at CAAT symposia were discussing when such an
alternative would be available.
While similar developments were
evident in Europe, there were large
segments of scientists outside industry that resisted the concept of alternatives in the United States. In fact,
important research institutions such
as the NIH avoided use of the term
“alternatives” whenever possible. For
example, the Health Research Extension Act of 1985 required the NIH to
establish an alternatives program, to
which the NIH gave the awkward title
“Biomedical Models and Materials
Resources.” A few years later, a Public
Health Service draft document on animal welfare commented that “efforts
have led to the discovery of research
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methods that are useful as ‘adjuncts’
to animal research, in that they complement animal models but rarely
replace them. Thus, these adjuncts
are not true ‘alternatives’—even the
use of this latter term can be misleading” (Public Health Service 1989).
A more balanced approach to the
issue was evident in the U.S. Office of
Technology Assessment’s landmark
report, “Alternatives to Animal Use in
Research, Testing and Education,”
which was produced by a government
office outside the orbit of the NIH and
Public Heath Service. In fact, in drafting the Animal Welfare Act, Congress
stipulated that the U.S. Department
of Agriculture, and not the Public
Health Service or its parent agency
(the Department of Health, Education, and Welfare, as it was then
known), oversee animal use in biomedical research.

The 1990s:
Alternatives
Begin to Be
Validated and
Accepted for
Regulatory Use
If the 1970s were marked by an
increase in interest in alternatives
and the ’80s by an increase in activity
on this front, the 1990s was a period
of maturation for the alternatives
approach. The field already had a few
academic centers, high-technology
companies, and journals dedicated to
the cause, as well as backing from
national laws. What it needed was a
better sense of when a new alternative
test was qualified to replace an animal test; in other words, What constituted adequate “validation” (Goldberg 1987)? The field also needed
more government-based centers not
only to partner with industry and others in validating alternative tests, but
perhaps more importantly, to give
their stamp of approval to adequately
validated tests, which would then

allow for regulatory acceptance.
In Europe both needs were
addressed by the establishment in
1992 of the European Centre for
the Validation of Alternative Methods (ECVAM), headed by Michael
Balls of FRAME (Table 5). ECVAM
took an active role in establishing
validation criteria and in funding
and managing validation programs
for promising alternative methods,
and it was the European Union’s
(EU) primary authority for approving alternative tests.
ECVAM’s counterpart in the United
States is the Interagency Coordinating
Committee on the Validation of Alternative Methods (ICCVAM), established
in 1994. ICCVAM was the successor to
the informal Interagency Regulatory
Alternatives Group and was an outgrowth of the NIH Revitalization Act of
1993. This legislation directed the
National Institute of Environmental
Health Sciences (NIEHS, one of the
NIH institutes) to establish criteria for
the validation and regulatory acceptance of alternative testing and to outline a process for regulatory review of
potential alternative methods. To
accomplish these tasks, the NIEHS
asked the various federal regulatory
and research-oriented agencies to
appoint representatives to an ad hoc
interagency committee to draft a
report. The ICCVAM report, “Validation and Regulatory Acceptance of
Toxicological Test Methods,” was
issued in 1997 (ICCVAM 1997). With
ICCVAM’s original mission accomplished, the participating federal agencies decided to change ICCVAM’s status from an ad hoc entity to a standing
committee to facilitate the ongoing
regulatory review and acceptance of
alternative methods. ICCVAM is
staffed by employees who have other
responsibilities to their parent agencies, so to facilitate ICCVAM’s new
role, the NIEHS established a support
center, the National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological
Methods (NICEATM) in 1998.
Several large-scale validation efforts
were launched during the 1990s, and
ECVAM played a role in many of these

through coordination, participation,
or funding. The establishment of
ECVAM and ICCVAM gave industry
the confidence to invest in new tests
and their validation, knowing that
regulatory authorities were available
to give advice on validation and
acceptance criteria and foster the
administrative process of regulatory
acceptance. The efforts of ECVAM,
ICCVAM, industry, and others began
to bear fruit in the late 1990s. In
1998 ECVAM endorsed the 3T3 Neutral Red Uptake Phototoxicity Test for
assessing phototoxicity and the
Transepithelial Electrical Resistance
Test and Episkin (and similar bioengineered skin constructs) for assessing
skin corrosivity. The same year
ECVAM also endorsed in vitro methods as alternatives to the ascites
(mouse-based) method for producing
monoclonal antibodies. The following
year, ICCVAM recommended Corrositex® for assessing skin corrosivity
and the Local Lymph Node Assay (a
reduction and refinement alternative) for assessing allergic contact
dermatitis. ICCVAM’s recommendations are not binding on the individual regulatory agencies (for example,
the Food and Drug Administration),
but may be accepted (or not) according to agency needs; so far the agencies have acted favorably on ICCVAM’s recommendations.
In addition to ICCVAM and ECVAM,
the OECD has emerged as a significant authority in the acceptance of
alternative methods. The OECD, an
international organization that facilitates trade, formally accepted the
Fixed Dose Procedure (in 1991), the
Acute Toxic Class Method (1993),
and the Up and Down Method (1997)
as reduction alternatives to the LD50
Test for acute toxicity (the Fixed Dose
Procedure is also a refinement alternative). In 1996 the OECD hosted a
workshop to develop internationally
harmonized criteria for the validation
and regulatory acceptance of alternative methods (OECD 1996).
The “internationalization” of the
alternatives field has also been aided
by the establishment of the triennial
World Congress on Alternatives and
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Table 5
Alternatives Chronology: 1990 –1999
1990

CAAT and ERGATT hold a workshop on validation
of alternative methods.

1993

The University of California Alternatives Center
is established at UC–Davis.
The Platform for Alternatives to Animal Experiments
in the Netherlands allocates the equivalent of
$700,000 annually for the promotion and validation
of research into the Three Rs and the improvement
of housing and care systems.

The first World Congress on Alternatives and Animal
Use in the Life Sciences: Education, Research, and
Testing, takes place in Baltimore.

The HSUS establishes the Russell and Burch Award
for scientists who have made outstanding
contributions to alternative methods.

Member states of the European Union agree on the
goal that everything possible should be done to
achieve a reduction of 50 percent in the use of
vertebrate animals for experimentation and other
scientific purposes by the year 2000.

The Japanese Society for Alternatives to Animal
Experimentation begins publishing the journal
AATEX (Alternatives to Animal Testing and
Experimentation).
1991

The Interagency Regulatory Alternatives Group holds
its second meeting on alternatives, in Washington, D.C.

The Interagency Regulatory Alternatives Group holds a
workshop, “Eye Irritation Testing Alternatives: Proposals
for Regulatory Consensus,” in Washington, D.C.
The HSUS presents Alan Goldberg, director of CAAT,
with the first Russell and Burch Award.

Dr. Michael Balls of FRAME is appointed director
of ECVAM.
1994

The OECD accepts the Fixed Dose Procedure as an
alternative to the LD50 Test.
Representatives of regulatory agencies in Japan,
Europe, and the United States agree to drop the
classic LD50 Test as a required measure of
acute toxicity.
The UK Home Office announces a grant program for
the funding of alternatives research.

1992

1995

The Gillette Company and The HSUS launch a
program to fund research and development of
alternative methods; two grants of $50,000 each
are awarded annually.

1996

The second World Congress on Alternatives and
Animal Use in the Life Sciences is held in Utrecht,
the Netherlands.

The European Centre for the Validation of Alternative
Methods (ECVAM) is established.

The OECD holds a workshop to develop
internationally harmonized criteria on validation
and regulatory acceptance.

The European Parliament amends the Cosmetic
Directive 76/768 to ban the marketing of cosmetics
tested on animals after January 1, 1998 (a decision
on the ban is later postponed until June 30, 2000).
CAAT hosts a tenth anniversary conference in
Baltimore, Md., giving Founders’ Awards to Dr. D.A.
Henderson, the CTFA, and Henry Spira.

The U.S. federal government establishes the
Interagency Coordinating Committee on the
Validation of Alternative Methods (ICCVAM),
co-chaired by William Stokes of NIEHS and
Richard Hill of EPA, in response to the
1993 NIH Revitalization Act.
The Netherlands Centre for Alternatives to Animal
Use (NCA) is established as a national information
center on alternatives.

The Second Report of the FRAME Toxicity Committee
is published in ATLA.
The Swiss Institute for Alternatives to Animal Testing
(SIAT) is established in Zurich.

The NIH Revitalization Act of 1993 directs the NIEHS
to establish criteria for the validation and regulatory
acceptance of alternative testing and to outline a
process for regulatory review of potential alternative
methods; it also directs the NIH director to establish
an alternatives program and to report on its
progress annually.

CAAT, The HSUS, Procter and Gamble, and other
organizations establish Altweb, a website devoted
to information on alternative methods.
1997

ICCVAM issues guidelines on criteria for validation
and regulatory acceptance of alternative methods.
The Institute for In Vitro Sciences is established
in Gaithersburg, Md.
(continued on next page)
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Table 5
Alternatives Chronology: 1990 –1999
1998

The HSUS presents the FDA’s Neil Wilcox and
ICCVAM’s William Stokes with the Russell and Burch
award for their contribution to the development
of alternatives.
ECVAM accepts the following alternative methods:
3T3 NRU PT test as an alternative for assessing
phototoxicity, Episkin and similar methods for assessing
skin corrosivity, and TER (transepithelial electrical
resistance) test for assessing skin corrosivity.
ECVAM endorses in vitro methods as alternatives
to the ascites method for the production of
monoclonal antibodies.
The National Toxicology Program Interagency
Center for the Evaluation of Alternative Toxicological
Methods (NICEATM) is established to provide
support to ICCVAM.

Animal Use in the Life Sciences, the
first of which was held in Baltimore in
1993 (Goldberg and van Zutphen
1995); the second in Utrecht, the
Netherlands, in 1996 (van Zutphen
and Balls 1997); and the third in
Bologna, Italy, in 1999. The international exchange of information on
alternatives was also given a boost
in 1996 with the establishment of
Altweb, an Internet web site spearheaded by CAAT, Procter and Gamble,
The HSUS, and others.
Political pressure played a significant role in moving the alternatives
issue during the 1990s, more directly
in Europe than in the United States.
The issue had some momentum of its
own, but outside pressure spurred
progress. In Europe, for example, the
European Parliament amended the
Cosmetic Directive 76/768 to ban
the marketing of cosmetics tested
on animals after January 1, 1998,
regardless of whether such testing
was conducted in Europe. Although a
decision on the marketing ban was
later postponed until June 30, 2000,
the Cosmetic Directive amendment
led to the formation of ECVAM and
encouraged research and development

1999

The third World Congress on Alternatives and Animal
Use in the Life Sciences is held in Bologna, Italy.
The HSUS presents Procter and Gamble scientist
Dr. Katherine Stitzel with the Russell and Burch
award for her contribution to the development
of alternatives.
CAAT holds TestSmart (a humane and efficient
approach to regulatory toxicity data) workshops in
order to discuss alternatives to animal testing in the
Environmental Protection Agency’s High Production
Volume (HPV) chemical testing program.
The EPA announces major changes in its HPV
program, including funding for alternative methods,
following the TestSmart workshops and negotiations
with animal protection organizations.
ICCVAM endorses Corrositex® for the assessment of
skin corrosivity and the Murine Local Lymph Node
Assay for the assessment of allergic contact dermatitis.

of alternatives by the European cosmetics trade association (COLIPA)
and others. The marketing ban would
have affected companies in the United States as well as in Europe, so the
amendment also kept some political
pressure focused on the issue in the
United States.
Since the most recent postponement of the marketing ban, a new
amendment (the seventh) has been
proposed. It calls for: (1) a ban on
animal testing of finished products in
the European Union as soon as the
directive comes into force, (2) a ban
on animal testing of cosmetic ingredients where alternatives are available, and (3) a complete ban on animal testing of cosmetic ingredients
within three years of implementation
of the directive, regardless of the
availability of alternatives. The
European Commission has stated that
only one two-year postponement of
the ingredients-testing ban would be
considered. Consequently, an absolute
ban on ingredients testing could
become effective within five years of
implementation of the directive.
Finally, the directive states that a
marketing ban, which would have

affected countries outside of the
European Union, will not occur due
to potential problems with World
Trade Organization rules; this effectively “kills” the proposed sixth
amendment.
Alternatives legislation in the United States in the 1990s was largely a
cooperative venture between industry and animal protection. The
alternatives language in the NIH Revitalization Act of 1993, which led to
the creation of ICCVAM, was the
product of efforts of several industry
and animal protection representatives working with Rep. Henry Waxman. A similar coalition led to the
introduction of the ICCVAM Authorization Act in the Senate (1999) and
House (2000) in an effort to strengthen ICCVAM and make it a permanent
entity. As of October 2000, this legislation was pending.

Discussion
Many animal protectionists are frustrated with the pace at which the use
of animals in research and testing is
being replaced, reduced, and refined.
However, the growth of the alterna-
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Abbreviations
ATLA

Alternatives to
Laboratory Animals

CAAT

Center for Alternatives
to Animal Testing

CAM

Chorio-Allantoic
Membrane

ERGATT

European Research
Group into Alternatives
in Toxicity Testing

FRAME

Fund for the
Replacement of Animals
in Medical Experiments

HPLC

High Pressure Liquid
Chromatography

IACUC

Institutional Animal
Care and Use
Committee

NAS

National Academy
of Sciences (USA)

NAVS

National Anti-Vivisection
Society (UK)

NIH

National Institutes
of Health (USA)

OECD

Organization for
Economic Cooperation
and Development

UFAW

Universities Federation
for Animal Welfare

ZEBET

Zentralstelle zur
Erfassung und
Bewertung von
Ergänzungs und
Ersatzmethoden zum
Tierversuch

tives field since the publication of
Russell and Burch’s seminal book in
1959 has been remarkable, especially
considering that the animal protection community itself did not
embrace the alternatives issue in a
significant way until the late 1970s.
During the 1980s cosmetics and consumer products companies began
investing millions of dollars into
research and development of alternatives, national governments incorporated the alternatives approach into
their animal protection legislation
and, in some cases, began funding
research and development of alterna132

tives, some companies began developing and marketing alternative test
kits, academic centers devoted to the
issue began to be established, and the
field of in vitro toxicology blossomed.
During the 1990s government centers devoted to the validation and regulator y acceptance of alternative
methods were established in Europe
and the United States, the triennial
World Congresses on Alternatives
began, and alternative tests began to
be formally approved and accepted by
regulatory agencies.
Have these developments translated into a decrease in the use of laboratory animals and in their levels of
pain and distress? Most countries
that keep records on the use of
research animals report a fall in laboratory animal numbers during the
1980s and 1990s, in some cases a dramatic fall (Rowan et al. 1995). The
statistics from the United Kingdom
show a decline in annual animal use
from around 5.5 million in 1976 to
2.7 million in 1998. Sir Peter
Medawar, who predicted in 1969 that
such a decline would begin in 1979 or
even earlier (Medawar 1972), was
obviously more far-sighted than the
Littlewood Committee, which reported in 1965 that animal use would not
be influenced by the development of
new (alternative) technology.
However, a key question is this:
How much of the decline in research
animal use in the United Kingdom
and in other countries has resulted
from pressure to develop and use
alternative methods? The available
data is not adequate to provide an
unequivocal answer. While other factors such as the cost of research animals and the increased sensitivity and
specificity of new techniques have no
doubt been important, it is also likely
that pressure from animal groups
(and progressive scientists) calling
for the development and use of “alternative” techniques has played a role
in reducing animal use. Animal protectionists certainly increased awareness of the Three Rs and humane
issues within the scientific community.
Technical developments over the
past thirty years have, for example,

reduced the demand for animals in
the production and testing of polio
vaccine and insulin (Hendriksen
1988; Trethewey 1989). Hendriksen
describes how the number of monkeys used in the production and testing of polio vaccine in the Netherlands was reduced from 4,570 in 1965
to 30 in 1984 by a series of technical
improvements, even though the actual amount of polio vaccine produced
was about the same in the two years.
The technical improvements were the
result of advances in molecular techniques and cell culture biology.
Trethewey describes a similar process in insulin testing that reduced
the demand for mice by 95 percent
between 1970 and 1986. The major
technical advance was the introduction of a mouse blood glucose test in
place of the mouse convulsion test.
This relatively nonstressful assay permitted the re-use of the same mouse
for more than one assay leading to a
further reduction in the number of
animals required. High Pressure Liquid Chromatography (HPLC) techniques have been developed and
introduced, and it is now possible to
standardize insulin preparations using
only a handful of mice to ensure that
each batch is biologically active. A
life-time supply of insulin for one diabetic now requires testing on the
equivalent of only a single mouse and
it is possible that mice will be eliminated altogether as further technical
advances are made.
Innovations in toxicity testing and
the standardization of therapeutics
such as insulin have reduced the
demand for animals in some procedures. However, the most significant
reductions have come in the search
for new drugs. As pharmaceutical
companies have switched from animal
to in vitro screens for agents with
potential therapeutic activity, they
have recorded dramatic decreases in
animal use. Hoffman–La Roche, for
example, reduced its annual animal
use from one million to about
300,000 without changing the number of new drug entities under investigation (Anonymous 1990). A switch
by the National Cancer Institute from
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a mouse screen for potential anticancer agents to human cancer cell
culture screens has resulted in a saving of several million mice per year
(Rowan and Andrutis 1990).
Russell (1995) attributes the development of replacement technology,
and the consequent decreases in laboratory animal use, to the waning
influence of what he and Burch
(1959) called the “high fidelity” fallacy—that models had to look like the
organism being modeled, no matter
what the power of the model to “discriminate” or elucidate the process
under study. Thus mammals such as
mice, dogs, and primates have historically been preferred as models of
humans because they have high fidelity to humans, not necessarily because
they have high discrimination. The
high fidelity fallacy has lost its currency as the power of low fidelity–
high discrimination techniques, such
as tissue culture and use of invertebrate species (for example, C. elegans) has been demonstrated.
The impact of refinements on animal pain and distress is even harder
to gauge than the impact of replacements and reductions on animal numbers. While animal numbers declined
during the 1980s and 1990s, increasing attention was being paid to the
neglected “R”—refinement—thanks
in part to new legislation in Europe
and the United States. In the United
Kingdom, the passage of the 1986
Scientific Procedures (Animals) Act
focused more attention on animal distress and led to a virtual doubling
(from 21 percent to 36 percent of all
procedures) in the rate of anesthetic
use in animal research in six years
(Anonymous 1990). In the United
States, protocol review by Institutional Animal Care and Use Committees
is increasingly focusing on reducing
animal pain and distress.
Two technical advances that will
significantly decrease pain and distress in laboratory animals are noninvasive imaging and telemetric
approaches to animal data (Stokstad
1999). These approaches not only
reduce or eliminate pain and distress,
they also allow for a 75 to 80 percent

reduction in animal numbers by
increasing the reliability of the data
and improving experimental design.
One of the major challenges in
making further progress in alternative methods is the indifference, if
not the antagonism, to the alternatives approach on the part of many
academic researchers worldwide.
While the NIH no longer automatically characterizes alternatives as
mere “adjuncts” of animal research,
and the NIEHS actively promotes
alternative methods, some biomedical research advocates have argued
that use of the term “alternatives”
implies that one needs to apologize
for using animals in research and
that this gives the public the wrong
impression (Goodwin 1992). While
such hostility to the alternatives
approach is abating, the field of alternatives would progress much faster if
academic researchers were more
sympathetic to the approach.
Another challenge in implementing
alternatives and in decreasing animal
use is the growth of genetic engineering, particularly in mice. The NIH’s
in-house use of mice reached a low of
about 300,000 in 1991 but has more
than doubled since then, according to
NIH Annual Reports and NIH Reports
to the USDA. Genetic engineering
can sometimes be harnessed to

reduce (and refine) animal use (Gordon 1991). It can also be argued that
the increasing numbers of genetically
engineered mice are at least somewhat offset by a corresponding
decrease in the use of other mice or
species, thereby nullifying any
increase in overall numbers. This
seems to be what is happening in the
United Kingdom, where the use of
genetically modified mice has gone
up tenfold, to around 500,000, but
total mouse use has fallen slightly. At
the very least, the impact of genetic
engineering on animal use should be
carefully monitored, given its potential to reverse the decreases in animal
use seen during the 1980s and 1990s.

Conclusion
The program that UFAW set in motion
in 1954 has born significant fruit.
Although Major Hume would no
doubt be surprised at the scope and
potential of biomedical science today,
he would be pleased at the growing
recognition accorded to Russell and
Burch (1959). The number of citations to Russell and Burch’s book in
the scientific literature increased
dramatically during the 1980s and,
especially, the 1990s (Figure 1).
In 1959 Hume spoke to an Ani-
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mal Care Panel meeting in Washington, D.C.:
A more recent event has been the
publication of a remarkable book
by Russell and Burch entitled The
Principles of Humane Experimental Technique. This deserves to
become a classic for all time, and
we have great hopes that it will
inaugurate a new field of systematic study. We hope that others
will follow up the lead it has given,
and that a generalized study of
humane technique, as a systematic component of the methodology
of research, will come to be considered essential to the training
of a biologist (Hume 1962).
This has indeed come to pass in the
Netherlands and other parts of
Europe (van Zutphen, Baumans, and
Beynen 1993), and we are hopeful
that the Three Rs will become fully
incorporated into the training of biologists in the United States.
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